SUMMARY A review of the records of 353 diabetic patients after a myocardial infarction confirmed the high mortality associated with the condition. The influence of improved diabetic control achieved by intravenous insulin was assessed in 64 patients and compared with earlier experience in a diabetic control group. The frequency of the major complications of myocardial infarction was unchanged and the death rate in both groups was identical (33%); even the patients with blood glucose concentrations >20 mmol/l on admission failed to benefit. Thus careful control of blood glucose concentrations after myocardial infarction in diabetic patients fails to improve the outcome of this high risk group. Mortality in diabetic patients after myocardial infarction is almost twice that of patients without diabetes mellitus.' 2 Improved metabolic control in the immediate period after infarction might reduce infarct size and influence survival. Insulin enhances the uptake of glucose, the major energy substrate of ischaemic myocardium,3 and reduces non-esterified fatty acid concentrations,4 which have been suggested to increase infarct size (by increasing myocardial oxygen consumption5 6) , reduce myocardial contractility,5 7 and be associated with postinfarction arrhythmias. 8 The aim of this study, therefore, was to determine whether the use of intravenous insulin reduced mortality in diabetic patients after a myocardial infarction. A group of patients treated in this way was compared with a control group comprising all diabetic patients admitted from 1967 to the beginning of the insulin infusion regimen in 1981. To discover whether changes in management had appreciably altered mortality over this period the death rate in all non-diabetic patients was calculated. Blood glucose values The blood glucose concentrations on admission were similar (the mean+ 1SD being 14-6+8-2 mmol/l in the control group and 16*1 ± 10-3 mmolI in the insulin infused group, the difference not being significant). By midday on the first full day after infarction the mean blood glucose concentration of the insulin infused group was 9-9+3*6 mmol/I compared with 12-4± 5*9 mmol/I for the control group, a difference that was statistically significant (p<0-01).
Outcome
There was no significant difference between the conventionally treated (control group) and the insulin infused patients in terms of the major complications of myocardial infarction: haemodynamic response (ranging from cardiac failure to cardiogenic shock), complete heart block, or ventricular fibrillation (primary or secondary) ( Table 2 ). The death rate in the control group was 33% (118 out of 353 patients) and 33% (21 out of 64 patients) in the insulin infused group. Clearly, there is no difference between these values, and the 95% confidence levels are + 12%. If the population mortality is 33% (based on the 353 control diabetic patients) then the maximum reduction in mortality that might be missed by chance at the 2-5% level is 36%. Of the 118 deaths in the control group, 110 were due to cardiac failure and eight to some other cause (five to strokes, two to renal failure, and one to bronchopneumonia); in the insulin infused group 20 died in cardiac failure and one as a result of a stroke.
It was thought possible that the benefit of insulin infusion might be restricted to those with high blood glucose concentrations on admission, but no such advantage was shown when the patient population was stratified according to the concentrations on admission ( Table 3) .
The total experience of managing diabetes over 16 years shows that the death rate remained constant from 30 to 33% whatever the treatment used (Figure) . For the insulin infused group, only the total death rate was computed, since the subsets divided according to prehospital treatment were too small for individual analysis.
Discussion
The death rate in diabetic patients who have a myocardial infarction is higher than for nondiabetics.' 2 In part this may be due to changes that occur before infarction. Diabetic patients have more extensive coronary atheroma'0-12 and so might be expected to have more extensive infarcts. A specific cardiomyopathyl3 14 has been reported in diabetes, and this may impair left ventricular function, which adds to the damage induced by infarction. Furthermore, some patients have an autonomic neuropathy, and the changed pain perception may alter the time taken to contact a doctor; moreover, the tachycardia of autonomic neuropathy could increase myocardial oxygen consumption. It is possible, however, that the metabolic changes induced at the time of infarction may also be of importance. The oxidation of non-esterified fatty acids is the major energy source of the normal myocardium, but ischaemic heart muscle depends largely on the anaerobic metabolism of glucose.3 The supply of glucose is partly curtailed by the infarction,'5 such that in diabetic patients, with residual insulin secretion, Gwilt, High concentrations of circulating non-esterified fatty acids are found after myocardial infarction.3 4 15 It has been suggested that they increase myocardial oxygen consumption56 and therefore may increase infarct size, compounding the effect of reduced glucose availability. Furthermore, high fatty acid concentrations may cause reduced contractility57 and increased frequency of arrhythmias.8 It would, therefore, seem possible that good metabolic control, by improving the glucose supply and reducing fatty acid concentrations, might reduce the mortality of myocardial infarction.
Little direct evidence exists to support this hypothesis, but a parallel is present with the use of glucose-insulin-potassium infusion. For many years it has been known that glucose and insulin can improve cardiac function,'920 and considerable interest arose from the suggestion of Sodi-Pallares et al, that glucose-insulin-potassium solutions reduce postinfarction arrhythmias.2' More recent work has suggested that infarct size in animals may be reduced22 23 and that pump function in man may be improved. 4 Translating this into the use of insulin for diabetic patients after infarction would suggest that intravenous insulin might be beneficial.
In this study the mortality of non-diabetic patients with myocardial infarction did not alter over the study period , and it, therefore, seemed reasonable to take a historical group comprising all diabetic patients admitted from 1967 to 1981 to compare with the insulin group. When the insulin infused and control groups are assessed there is no reduction in the hospital death rate. Furthermore, when patients are subdivided according to their blood glucose concentration on admission (Table 3) even those with the highest concentrations, who presumably are most likely to benefit from insulin infusion, show no improvement in prognosis. When the total diabetic sample is reviewed (Figure) the mortality remains constant at about 33% irrespective of the method of treatment used. Finally, the haemodynamic complication rate (Table 2) , the major predictor of outcome, had remained unchanged by the introduction of intravenous insulin. All these observations point to the same conclusion: survival in diabetic patients after myocardial infarction is not dependent on the excellence (or otherwise) of diabetic control.
The confidence levels of the diabetic mortality results are such that a reduction in mortality of 36% might just be missed by chance (at the 2-5% level), but in view of all the other observations pointing to the lack of improvement with intravenous insulin the likely benefit that might be missed must be much less.
The inability of good control to alter survival may be due to a number of factors. Firstly, it is possible that if a coronary artery is occluded then insulin also will be unable to reach the infarcted area and so improve the influx of glucose into these cells. Secondly, lipolysis is extremely sensitive24 to inhibition by insulin, and so, although non-esterified fatty acid concentrations will fall after insulin infusion, they may fall as quickly after subcutaneous insulin or the use of oral agents. Thirdly, it is probable that the high death rate in diabetic patients may be due to large myocardial infarcts, and then manipulation of cellular metabolism may have only a minor effect on outcome. It is also possible that our insulin regimen is still inadequate, as the mean blood glucose concentration in these patients does not fall within the normal nondiabetic range. Finally, the proportion of men in both diabetic groups was high, unlike the equal sex distribution usually seen in the diabetic population after a myocardial infarction,2 2 raising the possibility that local referral patterns may differ from the norm and so influence outcome.
The management of the diabetic patient after infarction remains debatable. Although a reduction in mortality has not been shown with intravenous insulin, it is possible that less easily detectable benefitssuch as reduction in infarct size-might occur; in addition, this insulin protocol provides a simple and effective way of controlling the inevitable dislocation of diabetic metabolism that occurs after myocardial infarction. For these reasons intravenous insulin infusion is used for the management of diabetic patients after coronary occlusion in our hospital.
